Halozyme CEO Says Dutch Ruling Hits Merck's Italian Keytruda Plant And Halozyme Has Sued It
CEO Helen Torley says Halozyme has not spoken to Merck, and the Dutch order covers eight markets that, with Germany, are about 20% of royalties.
Halozyme Therapeutics CEO Helen Torley said on the company's third-quarter earnings call Thursday that Halozyme has sued BSP Pharmaceutica, the Italian plant that makes Merck's subcutaneous Keytruda, directly for infringing its European patent. She also said Halozyme has had no conversations with Merck.
A suit aimed at the Italian plant
Halozyme, which licenses drug makers its ENHANZE technology so injected drugs can be given under the skin rather than by infusion, won a Dutch ruling on October 7 against Merck. The Specialized Dutch Patent Court in The Hague rejected Merck's challenges to Halozyme's EP622 patent and found Keytruda Culex infringing. It barred Merck's European marketing-approval holder from infringing in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.
A Morgan Stanley analyst asked whether the order, which does not distinguish between manufacturing for those countries and for export, could affect U.S. supply. Torley said the prohibition on Merck's approval holder and its affiliates, "we believe, does impact those entities' ability to supply Culex from BSP entity" regardless of the product's destination. Halozyme "has also taken some additional actions and has sued BSP directly for infringement of EP622," she said.
She stopped short on the U.S., saying Halozyme cannot comment on U.S. supply because it lacks full knowledge of Merck's worldwide supply chain.
No talks with Merck, and a harder U.S. fight
A Leerink Partners analyst said many observers were surprised Merck had not settled. Torley replied: "We haven't engaged in any conversations with Merck."
She said the eight Dutch-order markets plus Germany represent about 20% of total global royalties in Halozyme's experience with subcutaneous drugs, calling the ruling strategically important. Halozyme won a preliminary injunction in Germany in December 2025, when a Munich court ordered Merck to halt the launch, and in February 2026 the German Federal Patent Court gave a preliminary opinion that the patent is likely valid.
In the U.S., Torley conceded Merck has won initial rulings on Halozyme's separate patents, including adverse validity decisions on multiple post-grant reviews. She said she is confident of prevailing on appeal, which she expects will take likely until 2028.
Raised guidance and rising litigation costs
Total third-quarter revenue rose 39% to $493 million, and CFO Darren Snellgrove said the company now expects 2026 revenue of $1.86 billion to $1.925 billion, up $20 million at the midpoint. Royalty revenue climbed 44% to a record $341 million.
Selling, general and administrative expenses were $58.2 million, up from $46.1 million a year earlier, partly on consulting fees including litigation costs related to Merck, Snellgrove said.
Snellgrove said Halozyme plans to give 2027 guidance and a long-range outlook update when it next reports, and Torley said first HyperCon clinical starts are expected in the first half of 2027.
Sources
- Halozyme Therapeutics Q3 2026 Earnings Call Transcript — benzinga.com
- Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue Estimates — Yahoo Finance
- Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops — Yahoo Finance
- Halozyme Therapeutics Inc (HALO) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ... — Yahoo Finance
- Halozyme expects $1.86B-$1.925B 2026 revenue while raising non-GAAP EPS to $8.75-$9.05 (NASDAQ:HALO) | Seeking Alpha — seekingalpha.com